- Home
- ANIK vs SLS Comparison
ANIK vs SLS Comparison
Compare ANIK & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIK
- SLS
- Stock Information
- Founded
- ANIK 1983
- SLS 2012
- Country
- ANIK United States
- SLS United States
- Employees
- ANIK N/A
- SLS N/A
- Industry
- ANIK Medical/Dental Instruments
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- ANIK Health Care
- SLS Health Care
- Exchange
- ANIK Nasdaq
- SLS Nasdaq
- Market Cap
- ANIK 196.6M
- SLS 169.6M
- IPO Year
- ANIK 1993
- SLS N/A
- Fundamental
- Price
- ANIK $11.15
- SLS $1.71
- Analyst Decision
- ANIK Buy
- SLS
- Analyst Count
- ANIK 2
- SLS 0
- Target Price
- ANIK $21.50
- SLS N/A
- AVG Volume (30 Days)
- ANIK 79.2K
- SLS 3.0M
- Earning Date
- ANIK 05-09-2025
- SLS 05-13-2025
- Dividend Yield
- ANIK N/A
- SLS N/A
- EPS Growth
- ANIK N/A
- SLS N/A
- EPS
- ANIK N/A
- SLS N/A
- Revenue
- ANIK $117,053,000.00
- SLS N/A
- Revenue This Year
- ANIK N/A
- SLS N/A
- Revenue Next Year
- ANIK $9.70
- SLS N/A
- P/E Ratio
- ANIK N/A
- SLS N/A
- Revenue Growth
- ANIK 4.61
- SLS N/A
- 52 Week Low
- ANIK $10.89
- SLS $0.77
- 52 Week High
- ANIK $29.12
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- ANIK 33.63
- SLS 54.26
- Support Level
- ANIK $10.89
- SLS $1.36
- Resistance Level
- ANIK $11.44
- SLS $2.12
- Average True Range (ATR)
- ANIK 0.62
- SLS 0.18
- MACD
- ANIK -0.05
- SLS -0.01
- Stochastic Oscillator
- ANIK 14.44
- SLS 46.05
About ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.